Skip to main content
Top
Published in: Rheumatology International 3/2014

Open Access 01-03-2014 | Original Article

Sialic acid level reflects the disturbances of glycosylation and acute-phase reaction in rheumatic diseases

Authors: Lech Chrostek, Bogdan Cylwik, Ewa Gindzienska-Sieskiewicz, Ewa Gruszewska, Maciej Szmitkowski, Stanislaw Sierakowski

Published in: Rheumatology International | Issue 3/2014

Login to get access

Abstract

In the rheumatic diseases, the changes in the carbohydrate part of serum glycoproteins occur and these abnormalities can be monitored by serum level of total and free sialic acid. The aim of this study was to evaluate the total and free sialic acid level as a marker of inflammation activity (TSA) and the changes in glycosylation of blood glycoproteins (FSA) in rheumatoid arthritis (RA), systemic sclerosis (SSc) and systemic lupus erythematosus (SLE). Studies were carried out in 50 patients with RA, 24 with SLE and 32 with SSc. TSA concentration was measured with an enzymatic, colorimetric method and FSA with a thiobarbituric method. The serum levels of TSA in RA and SLE patients were significantly increased compared to controls and in RA patients were higher than that in SSc patients. The mean serum level of FSA in RA patients was significantly higher, but in SSc patients significantly lower than that in the controls, and in RA patients was significantly higher than in SLE and in SSc patients. All acute-phase proteins were changed: Positive acute-phase proteins were elevated, and the negative protein was decreased. The positive acute-phase proteins positively correlated with the levels of TSA and FSA in RA and SSc patients. In SLE patients, TSA positively correlated with haptoglobin and α1-antitrypsin. In RA patients, there was the positive correlation of TSA and FSA with DAS 28. The changes in the serum levels of TSA and FSA in the course of rheumatic diseases could reflect the abnormalities in glycosylation/sialylation patterns of glycoproteins induced by acute-phase response.
Literature
1.
go back to reference Raghav SK, Gupta B, Agrawal C, Saroha A, Das RH, Chaturvedi VP, Das HR (2006) Altered expression and glycosylation of plasma proteins in rheumatoid arthritis. Glycoconj J 23:167–173PubMedCrossRef Raghav SK, Gupta B, Agrawal C, Saroha A, Das RH, Chaturvedi VP, Das HR (2006) Altered expression and glycosylation of plasma proteins in rheumatoid arthritis. Glycoconj J 23:167–173PubMedCrossRef
3.
go back to reference Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670–673PubMedCrossRef Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670–673PubMedCrossRef
5.
go back to reference Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS (2007) Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44:1524–1534PubMedCrossRef Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS (2007) Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44:1524–1534PubMedCrossRef
6.
go back to reference Nimmerjahn F, Anthony RM, Ravetch JV (2007) Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci USA 104:8433–8437PubMedCrossRef Nimmerjahn F, Anthony RM, Ravetch JV (2007) Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci USA 104:8433–8437PubMedCrossRef
7.
go back to reference Przybysz M, Maszczak D, Borysewicz K, Szechinski J, Katnik-Prastowska I (2007) Relative sialylation and fucosylation of synovial and plasma fibronectins in relation to the progression and activity of rheumatoid arthritis. Glycoconj J 24:543–550PubMedCrossRef Przybysz M, Maszczak D, Borysewicz K, Szechinski J, Katnik-Prastowska I (2007) Relative sialylation and fucosylation of synovial and plasma fibronectins in relation to the progression and activity of rheumatoid arthritis. Glycoconj J 24:543–550PubMedCrossRef
8.
go back to reference Feelders RA, Vreugdenhil G, de Jong G, Swaak AJG, van Eijk HG (1992) Transferrin microheterogeneity in rheumatoid arthritis. Rheumatol Int 12:195–199PubMedCrossRef Feelders RA, Vreugdenhil G, de Jong G, Swaak AJG, van Eijk HG (1992) Transferrin microheterogeneity in rheumatoid arthritis. Rheumatol Int 12:195–199PubMedCrossRef
10.
go back to reference Cylwik B, Chrostek L, Gindzienska-Sieskiewicz E, Sierakowski S, Szmitkowski M (2010) Relationship between serum acute-phase proteins and high disease activity in patients with rheumatoid arthritis. Adv Med Sci 55:80–85. doi:10.2478/v10039-010-0006-7 PubMedCrossRef Cylwik B, Chrostek L, Gindzienska-Sieskiewicz E, Sierakowski S, Szmitkowski M (2010) Relationship between serum acute-phase proteins and high disease activity in patients with rheumatoid arthritis. Adv Med Sci 55:80–85. doi:10.​2478/​v10039-010-0006-7 PubMedCrossRef
11.
go back to reference Paul R, Rotzsch W (1989) The diagnostic significance of mucoproteins, sialic acid and cortisol in assessing the activity of rheumatic diseases. Z Gesamte Inn Med 44:410–413PubMed Paul R, Rotzsch W (1989) The diagnostic significance of mucoproteins, sialic acid and cortisol in assessing the activity of rheumatic diseases. Z Gesamte Inn Med 44:410–413PubMed
12.
go back to reference Alturfan AA, Uslu EU, Alturfan EE, Hatemi G, Fresko I, Kokoglu E (2007) Increased serum sialic acid levels in primary osteoarthritis and inactive rheumatoid arthritis. Tohoku J Exp Med 213:241–248PubMedCrossRef Alturfan AA, Uslu EU, Alturfan EE, Hatemi G, Fresko I, Kokoglu E (2007) Increased serum sialic acid levels in primary osteoarthritis and inactive rheumatoid arthritis. Tohoku J Exp Med 213:241–248PubMedCrossRef
13.
go back to reference Skoza L, Mohos S (1976) Stable thiobarbituric acid chromophore with dimethyl sulphoxide. Application to sialic acid assays in analytical De-O-acetylation. Biochem J 159:457–462PubMed Skoza L, Mohos S (1976) Stable thiobarbituric acid chromophore with dimethyl sulphoxide. Application to sialic acid assays in analytical De-O-acetylation. Biochem J 159:457–462PubMed
15.
go back to reference Pasek M, Duk M, Podbielska M, Sokolik R, Szechinski J, Lisowska E, Krotkiewski H (2006) Galactosylation of IgG from rheumatoid arthritis (RA) patients: changes during therapy. Glycoconj J 23:463–471PubMedCrossRef Pasek M, Duk M, Podbielska M, Sokolik R, Szechinski J, Lisowska E, Krotkiewski H (2006) Galactosylation of IgG from rheumatoid arthritis (RA) patients: changes during therapy. Glycoconj J 23:463–471PubMedCrossRef
16.
go back to reference Gornik I, Maravic G, Dumic J, Flogel M, Lauc G (1999) Fucosylation of IgG heavy chains is increased in rheumatoid arthritis. Clin Biochem 32:605–608PubMedCrossRef Gornik I, Maravic G, Dumic J, Flogel M, Lauc G (1999) Fucosylation of IgG heavy chains is increased in rheumatoid arthritis. Clin Biochem 32:605–608PubMedCrossRef
17.
go back to reference Matsumoto A, Shikata K, Takeuchi F, Kojima N, Mizuochi T (2000) Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation. J Biochem 128:621–628PubMedCrossRef Matsumoto A, Shikata K, Takeuchi F, Kojima N, Mizuochi T (2000) Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation. J Biochem 128:621–628PubMedCrossRef
18.
go back to reference Maury CP, Helve T, Sjöblom C (1982) Serum beta 2-microglobulin, sialic acid, and C-reactive protein in systemic lupus erythematosus. Rheumatol Int 2:145–149PubMedCrossRef Maury CP, Helve T, Sjöblom C (1982) Serum beta 2-microglobulin, sialic acid, and C-reactive protein in systemic lupus erythematosus. Rheumatol Int 2:145–149PubMedCrossRef
19.
go back to reference Ota T, Uemura A, Eto S, Suzuki H (1985) Clinical significance of serum sialic acid in rheumatoid arthritis and systemic lupus erythematosus. J Uoeh 7:401–407PubMed Ota T, Uemura A, Eto S, Suzuki H (1985) Clinical significance of serum sialic acid in rheumatoid arthritis and systemic lupus erythematosus. J Uoeh 7:401–407PubMed
20.
go back to reference Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454PubMedCrossRef Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454PubMedCrossRef
22.
go back to reference Silva I, Mateus M, Branco JC (2010) Assessment of erythrocyte sedimentation rate (ESR) and C- reactive protein (CRP) on rheumatoid arthritis activity prediction. Acta Rheumatol Port 35:456–462 Silva I, Mateus M, Branco JC (2010) Assessment of erythrocyte sedimentation rate (ESR) and C- reactive protein (CRP) on rheumatoid arthritis activity prediction. Acta Rheumatol Port 35:456–462
23.
go back to reference Pepys MB, Lanham JG, De Beer FC (1982) C-reactive protein in SLE. Clin Rheum Dis 8:91–103PubMed Pepys MB, Lanham JG, De Beer FC (1982) C-reactive protein in SLE. Clin Rheum Dis 8:91–103PubMed
24.
go back to reference Bell SA, Faust H, Schmid A, Meurer M (1998) Autoantibodies to C-reactive protein and other acute-phase proteins in systemic autoimmune diseases. Clin Exp Immunol 113:327–332PubMedCentralPubMedCrossRef Bell SA, Faust H, Schmid A, Meurer M (1998) Autoantibodies to C-reactive protein and other acute-phase proteins in systemic autoimmune diseases. Clin Exp Immunol 113:327–332PubMedCentralPubMedCrossRef
25.
go back to reference Kovacs A, Green F, Hansson LO, Lundman P, Samnegard A, Boquist S, Ericsson CG, Watkins H, Hamsten A, Tornvall P (2005) A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis 178:193–198PubMedCrossRef Kovacs A, Green F, Hansson LO, Lundman P, Samnegard A, Boquist S, Ericsson CG, Watkins H, Hamsten A, Tornvall P (2005) A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis 178:193–198PubMedCrossRef
26.
go back to reference Muangchan C, Harding S, Khimdas S, Bonner A, The Canadian Scleroderma Research Group, Baron M, Pope J (2012) Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian scleroderma research group. Arthritis Care Res 64:1405–1414. doi:10.1002/acr.21716 CrossRef Muangchan C, Harding S, Khimdas S, Bonner A, The Canadian Scleroderma Research Group, Baron M, Pope J (2012) Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian scleroderma research group. Arthritis Care Res 64:1405–1414. doi:10.​1002/​acr.​21716 CrossRef
27.
go back to reference Ceciliani F, Pocacqua V (2007) The acute phase protein α1-acid glycoprotein: a model for altered glycosylation during diseases. Curr Protein Peptide Sci 8:91–108CrossRef Ceciliani F, Pocacqua V (2007) The acute phase protein α1-acid glycoprotein: a model for altered glycosylation during diseases. Curr Protein Peptide Sci 8:91–108CrossRef
28.
go back to reference Treuheit MJ, Halsall HB (1992) Disease-coupled specificity in the glycan structures of orosomucoid. Clin Chim Acta 210:237–239PubMedCrossRef Treuheit MJ, Halsall HB (1992) Disease-coupled specificity in the glycan structures of orosomucoid. Clin Chim Acta 210:237–239PubMedCrossRef
29.
go back to reference De Graaf TW, Van der Stelt ME, Anbergen MG, van Dijk W (1993) Inflammation-induced expression of sialyl Lewis X-containing glycan structures on alpha 1-acid glycoprotein (orosomucoid) in human sera. J Exp Med 177:657–666PubMedCrossRef De Graaf TW, Van der Stelt ME, Anbergen MG, van Dijk W (1993) Inflammation-induced expression of sialyl Lewis X-containing glycan structures on alpha 1-acid glycoprotein (orosomucoid) in human sera. J Exp Med 177:657–666PubMedCrossRef
Metadata
Title
Sialic acid level reflects the disturbances of glycosylation and acute-phase reaction in rheumatic diseases
Authors
Lech Chrostek
Bogdan Cylwik
Ewa Gindzienska-Sieskiewicz
Ewa Gruszewska
Maciej Szmitkowski
Stanislaw Sierakowski
Publication date
01-03-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 3/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2921-y

Other articles of this Issue 3/2014

Rheumatology International 3/2014 Go to the issue